Spruce Biosciences presented a late-breaking poster at the Annual Meeting of the Endocrine Society (ENDO 2019) outlining positive results from a phase II trial of tildacerfont for congenital adrenal hyperplasia (CAH). The multicenter, multiple-dose, dose-escalation...